SHAREHOLDER ALERT: Lundin Law PC Announces an Investigation of Alcobra, Ltd. and Encourages Investors with Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / February 24, 2017 / Lundin Law PC, a shareholder rights firm, announces that it is investigating claims against Alcobra, Ltd. (“Alcobra” or the “Company”) (NASDAQ: ADHD) concerning possible violations of federal securities laws.

To get more information about this investigation, please contact Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or via email at brian@lundinlawpc.com.

The investigation is centered on whether Alcobra and some of its officers and/or directors have violated Sections 10(b) and 20(a) of the Securities Exchange Act of 1934.

Alcobra is a biopharmaceutical company that develops and sells oral drug candidates. On January 17, 2017, Alcobra revealed that the Company’s attention deficit hyperactivity disorder drug, Metadoxine Extended Release, was unsuccessful in reaching its primary endpoint during a Phase 3 trial. When this information was released to the investing public, the value of Alcobra declined, causing investors serious harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com

http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 455942